Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Journal of Thoracic Oncology Année : 2020

Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome

Maria Jove
  • Fonction : Auteur
Ernest Nadal
  • Fonction : Auteur
Marion Dhooge
  • Fonction : Auteur
Alex Teulé
  • Fonction : Auteur
  • PersonId : 922717
Jose-Valero Álvarez
  • Fonction : Auteur
Mireia Menéndez
  • Fonction : Auteur
Juana Saldaña
  • Fonction : Auteur
Pilar Lianes
  • Fonction : Auteur
Édouard Auclin
  • Fonction : Auteur
Emma Green
  • Fonction : Auteur
Gabriel Capellà
  • Fonction : Auteur
Etienne Rouleau
  • Fonction : Auteur
  • PersonId : 889842
Conxi Lazaro
  • Fonction : Auteur
  • PersonId : 882455

Résumé

Introduction - Actionable somatic molecular alterations are found in 15% to 20% of NSCLC in Europe. NSCLC is a tumor observed in patients with germline TP53 variants causing Li-Fraumeni syndrome (LFS), but its somatic molecular profile is unknown. Methods - Retrospective study of clinical and molecular profiles of patients with NSCLC and germline TP53 variants. Results - Among 22 patients with NSCLC and LFS (n = 23 lung tumors), 64% were women, median age was 51 years, 84% were nonsmokers, 73% had adenocarcinoma histological subtype, and 84% were diagnosed with advanced-stage disease. These patients harbored 16 distinct germline TP53 variants; the most common was p.R158H (5/22; three in the same family). Personal and family histories of cancer were reported in 71% and 90% of patients, respectively. In most cases (87%, 13/15), lung cancer was diagnosed with a late onset. Of the 21 tumors analyzed, somatic oncogenic driver mutations were found in 19 of 21 (90%), EGFR mutations in 18 (exon 19 deletion in 12 cases, L858R in three cases, and G719A, exon 20 insertion, and missing mutation subtype, each with one case), and ROS1 fusion in one case. A PI3KCA mutation was concurrently detected at diagnosis in three EGFR exon 19-deleted tumors (3/12). The median overall survival was 37.3 months in 14 patients treated with EGFR inhibitors; seven developed resistance, five (71%) acquired EGFR-T790M mutation, and one had SCLC transformation. Conclusions - Driver oncogenic alterations were observed in 90% of the LFS tumors, mainly EGFR mutations; one ROS1 fusion was also observed. The germline TP53 variants and lung cancer carcinogenesis driven by oncogenic processes need further evaluation.

Dates et versions

hal-02534435 , version 1 (07-04-2020)

Identifiants

Citer

Laura Mezquita, Maria Jove, Ernest Nadal, Maria Kfoury, Teresa Morán, et al.. Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome. Journal of Thoracic Oncology, 2020, 15 (7), pp.1232-1239. ⟨10.1016/j.jtho.2020.03.005⟩. ⟨hal-02534435⟩
83 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More